The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), managed by ATI, continues to strengthen the U.S. bio-industrial base through investments in scalable biomanufacturing and advanced chemical processing.

One example is a project award the BioMaP-Consortium facilitated on behalf of the U.S. Department of Health and Human Services Defense Production Act Title III Program. This award was made to Manus, a world-leading scale-up platform

of bioalternatives, supporting efforts to secure natural-product-based essential medicines through integrated biosynthesis, scalable precursor manufacturing, and continuous-flow semisynthetic chemistry.Awarded in November 2024 and valued at up to $32.4 million, this project establishes a U.S.-based manufacturing platform for natural-product-derived essential medicines at Manus’ 44-acre Augusta, Georgia, BioFacility. The investment directly addresses longstanding supply chain vulnerabilities for natural-product Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), many of which remain susceptible to shortages driven by agricultural variability, low-yield botanical extraction, and reliance on foreign suppliers. Manus’ integrated approach shifts this paradigm by pairing industrial-scale biosynthesis of Natural Product (NP) intermediates with ArtemiFlow USA’s flow chemistry technology, enabling efficient, reproducible, and scalable conversion of biologically produced scaffolds into finished KSMs and APIs.

This 24-month project expands U.S. control over the molecular supply chain by integrating advanced biosynthesis with state-of-the-art chemical processing. The effort will:

• Establish domestic infrastructure for natural-product KSM production
• Scale fermentation-based manufacturing
• Deploy continuous-flow reactors for high-efficiency multi-step NP transformations
• Strengthen U.S. preparedness for essential medicines with historically fragile supply chains
• Enable future expansion to a broader suite of NP- derived APIs

This award underscores the BioMaP-Consortium’s commitment to expanding U.S. capacity for critical material bioproduction, securing supply chains against import disruptions, accelerating the industrial adoption of biotechnology and continuous processing, and advancing distributed manufacturing to support national preparedness. By combining large-scale biosynthesis with advanced continuous-flow chemistry, Manus is establishing a fully integrated manufacturing platform that delivers both immediate and long-term national value. This system enables U.S.-based production of Artemisinin under Current Good Manufacturing Practices (CGMP)-aligned continuous processes, provides a reliable end-to-end model for natural-product medicines prone to shortages, and creates a scalable, modular infrastructure capable of supporting additional NP-derived APIs as public health needs evolve. Together, this project sets a new benchmark for how biotechnology, chemical engineering, and distributed manufacturing can be leveraged to safeguard access to critical therapies, illustrating the tangible impact of coordinated national investment in biomanufacturing, process intensification, and pharmaceutical supply chain resilience.